Sugi Predict

Sugi Predict / Targets / APH1B

APH1B

Gamma-secretase subunit APH-1B (APH-1b) (Aph- · Q8WW43 · APH1B on Sugi Atlas →

142,309 patent compounds predicted against APH1B, 74,941 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL33171 SCHEMBL33171 1.00 20/20
SCHEMBL137789 SCHEMBL137789 1.00 20/20
SCHEMBL139302 SCHEMBL139302 1.00 20/20
Mrk-560 Mrk-560 (SCHEMBL237758) 1.00 20/20
Mrk-560 Mrk-560 (SCHEMBL237759) 1.00 20/20
Mrk-560 Mrk-560 (SCHEMBL237760) 1.00 20/20
SCHEMBL136503 SCHEMBL136503 0.76 20/20
SCHEMBL154957 SCHEMBL154957 0.66 20/20
SCHEMBL138898 SCHEMBL138898 0.66 20/20
SCHEMBL139605 SCHEMBL139605 0.66 20/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL154119) 0.65 20/20
SCHEMBL139065 SCHEMBL139065 0.64 20/20
SCHEMBL151407 SCHEMBL151407 0.62 20/20
SCHEMBL138968 SCHEMBL138968 0.61 20/20
SCHEMBL139498 SCHEMBL139498 0.60 20/20
SCHEMBL154717 SCHEMBL154717 0.58 20/20
SCHEMBL139470 SCHEMBL139470 0.58 20/20
SCHEMBL139515 SCHEMBL139515 0.58 20/20
SCHEMBL139460 SCHEMBL139460 0.58 20/20
SCHEMBL155625 SCHEMBL155625 0.57 20/20

Clinical trials — most relevant to APH1B by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Neptune Krill Oil (NKO™) in Early Stage Alzheimer's Disease (MNEMOSYNE) PHASE4COMPLETED
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. PHASE2/PHASE3COMPLETED
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001 PHASE2/PHASE3ACTIVE_NOT_RECRUITING
A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation PHASE2/PHASE3RECRUITING
A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation PHASE2/PHASE3RECRUITING
Bridging Study of C11 Pittsburgh Compound B (PiB) and F18 Flutemetamol Brain Positron Emission Tomography (PET) PHASE2COMPLETED
A Single Site, Randomized, Double-blind, Placebo Controlled Trial of NIC5-15 in Subjects With Alzheimer's Disease PHASE2COMPLETED
Development of NIC5-15 in the Treatment of Alzheimer's Disease PHASE2COMPLETED
Study of APH-1105 in Patients With Mild to Moderate Alzheimer's Disease PHASE2UNKNOWN
MABp1 IN HIDRADENITIS SUPPURATIVA REFRACTORY TO ADALIMUMAB PHASE2COMPLETED
Sirtuin-NAD Activator in Alzheimer's Disease PHASE1/PHASE2ACTIVE_NOT_RECRUITING
Feasibility Study in Subjects With Mild to Moderate Alzheimer's Disease PHASE1/PHASE2COMPLETED
Gamma-secretase/Notch Signalling Pathway Inhibitor RO4929097 in Combination With Cisplatin, Vinblastine, and Temozolomide in Treating Patients With Recurrent or Metastatic Melanoma PHASE1/PHASE2COMPLETED
Alzheimer's Disease Acitretin Medication PHASE2COMPLETED
Neurogenetic Pharmaceuticals (NGP) 555 in Healthy Young Volunteers (Single-ascending Dose) PHASE1COMPLETED
Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors PHASE1COMPLETED
Phenserine on the Alzheimer's Treatment Horizon, Study 1 PHASE1COMPLETED
Choline Effects - Pre-symptomatic AD PHASE1COMPLETED
PET Imaging of Brain Amyloid Using [11C]MeS-IMPY PHASE1COMPLETED
Exploratory and Safety Study of [F-18]W372 EARLY_PHASE1COMPLETED
Dominantly Inherited Alzheimer Network (DIAN) nanRECRUITING
Late Onset Alzheimer's Disease nanRECRUITING
Bace1as Role in Heart Failure (BACE1AS-HF) nanCOMPLETED
Online Neuropsychological Test Validation Project With Imaging Pilot nanCOMPLETED
The Evaluation and Follow-up of Individuals With Memory Disorder nanCOMPLETED
Clearance Mechanisms in Atypical Neurodegenerative Diseases nanUNKNOWN
Phenotypic and Molecular Characterisation of Cerebral Amyloid Angiopathy nanRECRUITING
Identification of New FTLD Genes nanUNKNOWN
AusCADASIL: An Australian Cohort of CADASIL nanRECRUITING
Biomarker Study for Alzheimer's Disease nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a APH1B binder may also engage these)

ProteinNameSimilarity
Q5RDM3 — 1.000 Q5RDM3 →
Q9DCZ9 — 1.000 Q9DCZ9 →
Q8C7N7 — 1.000 Q8C7N7 →
APH1A Gamma-secretase subunit APH-1A (APH-1a) (Aph- 0.996 landscape →
Q9VQG2 — 0.996 Q9VQG2 →
Q8JHE9 — 0.995 Q8JHE9 →
Q8BVF7 — 0.993 Q8BVF7 →
Q8L9G7 — 0.992 Q8L9G7 →
O45876 — 0.985 O45876 →
Q9P055 — 0.980 Q9P055 →
Q8BI36 — 0.979 Q8BI36 →
Q2TA63 — 0.978 Q2TA63 →
A0A8I3MKU8 — 0.977 A0A8I3MKU8 →
Q9CQG6 — 0.977 Q9CQG6 →
Q07326 — 0.975 Q07326 →
P25618 — 0.975 P25618 →
B4N5D3 — 0.975 B4N5D3 →
I6VSD2 — 0.975 I6VSD2 →
B4J2W3 — 0.974 B4J2W3 →
Q9BVK8 — 0.974 Q9BVK8 →
B4LC58 — 0.974 B4LC58 →
Q9JJK1 — 0.974 Q9JJK1 →
Q3SZR6 — 0.974 Q3SZR6 →
Q28FY5 — 0.974 Q28FY5 →
B4HEB1 — 0.974 B4HEB1 →
Q5FWM8 — 0.973 Q5FWM8 →
Q0V9G6 — 0.973 Q0V9G6 →
A2XX57 — 0.973 A2XX57 →
F4K2U8 — 0.973 F4K2U8 →
B0CMA4 — 0.973 B0CMA4 →